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Summary 
Interleukin 12 (IL-12) doses in excess of 100 ng/d have been shown to induce profound immunotox- 
icities in mice infected with lymphocytic choriomeningitis virus (LCMV). These immunotoxici- 
ties are characterized  by almost complete inhibition of virus-induced CD8 + T  cell expansion 
and CTL activation, and up to 2 log increases in viral replication. They are accompanied by 
induction of serum tumor necrosis factor (TNF). The studies presented here were undertaken 
to characterize mechanisms for the I1:12-induced toxicities and to examine expression and func- 
tion of TNF in this context. Several physiological changes were induced in I1:12-treated unin- 
fected and dramatically elevated in I1:12-treated virus-infected mice. I1:12 induced (a) decreases 
in body weights, >10% in uninfected and ~20% in LCMV-infected mice; (b) elevation of cir- 
culating glucocorticoid levels to >10/~g/dl in uninfected and >20/zg/dl in infected mice; and 
(c) decreases in thymic mass, >30% in uninfected and up to 95% in infected mice. These changes 
are known to be associated with circulating TNF. Northern blot and in situ hybridization anal- 
yses demonstrated that I1:12 induced TNF-ol expression and that LCMV infection synergized 
with I1:12 for induction of this factor. Antibodies neutralizing TNF reversed all of the I1:12-in- 
duced toxicities in LCMV-infected mice including the immunotoxicities against CD8 § T cells 
and anti-viral defenses. The TNF-mediated immunotoxicities appeared to result from an induced 
cellular sensitivity to the factor,  as splenic leukocytes and CD8 + T  cell subsets isolated from 
LCMV-infected  mice were more sensitive to TNF-mediated cytotoxicity in culture than were 
equivalent populations prepared from uninfected mice. Experiments with the glucocorticoid type 
II receptor antagonist, RU486, demonstrated that endogenous glucocorticoids were secondary 
intermediaries in I1:12-induced thymic atrophy.  Studies in I1:2-deficient mice showed that the 
synergism was dependent upon endogenous I1:2. The results delineate a unique mechanism of 
TNF-mediated toxicity.  In addition,  they have significant  implications concerning potential 
detrimental consequences of in vivo TNF induction and of I1:12 administration for protective 
anti-viral  responses. 
I 
L-12 is a heterodimeric cytokine with potent biological effects 
in vitro and in vivo (reviewed in reference 1). I1:12 has 
been shown to (a) induce IFN-3, production, (b) augment 
cytotoxic function and proliferation of NK and activated T 
cells, and (c) promote Th-1 type cytokine responses. In vitro 
experiments have demonstrated that several I1:12-mediated 
functions require tumor necrosis factor (TNF) (2, 3).  En- 
dogenous I1:12 is clearly important for protective immune 
responses during acute infections with intracellular parasites 
(4) and bacteria (5). Murine studies have demonstrated that 
I1:12 administration at doses greater than or equal to 100 
ng/d can  enhance protective immune responses  to  these 
pathogens (4, 6, 7) as well as to tumors (8). Therefore, in 
the context of endogenous responses, administration of the 
factor  can be beneficial in promoting protective responses 
against  diseases resulting from these challenges. 
Little is known about II:12 expression  and function for 
protective responses against acute viral infections.  The early 
studies examining consequences of administering I1:12 during 
experimental murine infections indicate that effects of this 
factor can be very different in the context of the endogenous 
cellular and cytokine responses to viral infections (7, 9). We 
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phocytic choriomeningitis virus (LCMV)  1 (9).  The endog- 
enous immune response  to this virus is characterized by a 
profound increase in CD8 + T  cell numbers,  activation of 
virus-specific  CTLs, restricted to class I histocompatibility 
molecules, and interleukin-2 (I1:2) expression at 7-10 d after 
infection (10, 11). In this model, the effects of IL-12 adminis- 
tration are pleiotropic and dose dependent (9).  Low doses 
of I1:12 (1-10 ng/d) enhance, whereas high doses (100-1,000 
ng/d) inhibit CD8 + T cell responses. Both CD8 + T cell ex- 
pansion and presence of virus-specific CTLs are reduced with 
the higher doses.  CD8 + T  cell responses  are required for 
LCMV clearance (12), and viral replication is increased in these 
mice (9). As high dose I1:12 administration induces numerous 
necrotic lesions and apoptotic cells in lymphoid tissue,  the 
effects on T cell responses  appear to be associated with cell 
death. Therefore, doses of I1:12 which are immune enhancing 
and resistance promoting in the context of other infections 
or tumors, can be detrimental during viral  infection. 
High doses of II.,12 also induce serum TNF levels of 50-125 
pg/ml in uninfected and 85-200 pg/ml in LCMV-infected 
mice (9). TNF is known to mediate a variety of biological 
activities and elicit a number of physiological and patholog- 
ical changes. At high concentrations, this factor can promote 
weight loss or wasting (13, 14). In addition, systemic TNF 
can induce circulating glucocorticoids (15, 16), and glucocor- 
ticoids can promote thymic atrophy (17, 18). Moreover, TNF 
can mediate cell killing directly (19), or indirectly through 
induction of glucocorticoids (17, 20, 21). As there is syner- 
gism for II:12 induction of TNF during viral infections, these 
other toxicities also may be induced in virus-infected mice 
treated with I1:12. 
The studies presented here were performed to further char- 
acterize I1:12-induced effects in vivo and to identify mecha- 
nisms for IL-12-induced  toxicities.  The results show that in 
addition  to  inducing  profound  reductions  in  responding 
CD8 + T cells, I1:12 administration acts synergistically with 
infection to induce wasting, thymic atrophy, and elevated cor- 
ticosterone,  the natural glucocorticoid of mouse. All of these 
parameters,  including the CD8 + T  cell immunotoxicities, 
are dependent upon endogenous TNF expression. The effects 
on thymic organs,  but  not  CD8 +  T  cell  reductions,  are 
glucocorticoid-mediated. These data have significant impli- 
cations concerning in vivo cytokine interaction, and conse- 
quences of administered cytokines in the context of ongoing 
immune responses.  They also suggest a pathway by which 
infection with agents inducing I1:12 and/or TNF, during a 
viral infection, might dramatically limit protective anti-viral 
immune responses and induce physiologically adverse effects 
on the host. 
Materials  and Methods 
Mice.  Specific  pathogen-free  male 4-wk-old C57BL/6 mice were 
purchased from Taconic  Laboratory  Animals  and Services (German- 
1 Abbreviations used in this paper: DIG, digoxigenin;  GAPDH, glyceralde- 
hyde 3-phosphate dehydrogenase;  I_CMV, lymphocytic  choriomeningitis 
virus; SSC, sodium chloride sodium citrate buffer. 
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town, NY). Animals were 6-12 wk old at time of experiments. 
Mice possessing a mutated IL-2  gene were a gift of  Dr. Ivan Horak 
(Institute of Virology and Immunobiology, University of Wurz- 
burg, Wurzburg, Germany) (22). Male founder mice were mated 
with C57BL/6 females ('laconic) and heterozygous progeny used 
to establish a mutant 11.-2 colony in our pathogen-free facilities  at 
Brown University.  Heterozygous  matings were set up and ofspring 
genetically  identified  utilizing the polymerase  chain reaction (PCR). 
I1.,2 +/- and IL-2  -/- mice were between 4 and 7 wk when used. 
All animals were maintained in a 12-h light/dark cycle  with lights 
on at 7 A.M. Mice were sacrificed  by cervical dislocation. Proce- 
dures were carried out in accordance with institutional guidelines 
for animal care and use. 
Cytokines  and  Cytokine  Assays.  Murine  rlL-12 (a  gift from 
Genetics Institute, Inc., Cambridge, MA) was expressed from cloned 
cDNAs (23) provided  by Drs. David Schoenhaut and Ueli Gubler 
(Hoffman-La  Roche, Inc., Nutley, NJ). All experiments presented 
here were performed  with lot MRB630717292A which had a spedfic 
activity of 8.4  x  106 U/mg (24). Endotoxin contamination, as 
measured in the Limulus amebocyte  assay, was <1.8 EU/mg. Con- 
centrated aliquots of IL-12 were stored at  -90~  and diluted in 
PBS containing  5% heat-inactivated  male C57BL/6 serum (Taconic) 
immediately before use. Murine rTNF-c~ (endotoxin contamina- 
tion of <0.1 ng/#g), purchased from R & D Systems, Inc. (Min- 
neapolis, MN),  was  reconstituted  according to  manufacturer 
specifications. Serum TNF was measured by ELISA using either 
commercially prepared kits  from Genzyme Corporation  (Cam- 
bridge, MA) or commercially  available  reagents  described as follows. 
Capture hamster anti-mouse TNF antibody, TN3.19-12 (25), was 
used at 10 #g/ml to coat Immulon 4 microtiter plates (Dynatech 
Laboratories, Chantilly, VA). After sample incubation at 37~ 
bound TNF was detected with rabbit polyclonal anti-TNF (En- 
dogen, Inc., Cambridge, MA) at 5 #g/ml, peroxidase-conjugated 
donkey anti-rabbit IgG (Jackson ImmunoResearch, West Grove, 
PA) at 3 #g/ml, and the substrate ABTS (2.2:azino-di [3-ethyl- 
benzthiazoline sulfonate 6]) (Kirkegaard and Perry Labs, Gaithers- 
burg, MD). Colorimetric changes in ELISAs were read at either 
490 or 410, respectively,  using a Dynatech MR 4000 plate reader. 
rlL-2 was a gift of Cetus Corp. and had a specific  activity of 1.8 x 
107 IU/mg. 
In Vivo Treatment Protocols.  Mice  were either uninfected or in- 
fected i.p. with 2.5  x  104 PFU LCMV Armstrong strain clone 
E350. Except where specified, animals were treated with 100 #1 
vehicle, or vehicle containing 500 ng ID12 (this dose of IL-12 is 
also referred to as "high dose"). In LCMV-infected  mice, first in- 
jections were given 6 h after infection. Mice were treated with I~12 
or vehicle on each subsequent day for a total of seven injections. 
IL-2-treated  mice  were given 1,000 ng II.-2  per day. Where specified, 
mice were weighed using a portable digital scale (Ohaus, Florham 
Park, NJ) starting on day 0 before any injections were given, and 
then on each day after infection. Individual mice were identified 
by ear and/or toe markings. Samples for serum corticosterone  were 
obtained retroorbitally, after methoxyflurane anesthesia (Pittman- 
Moore, Mundelein, IL), at the beginning of the light cycle (7- 
8 A.M.) under low stress conditions, i.e., in less than 4 min from 
time of animal handling. 
To evaluate functions of endogenous glucocorticoids in II.r12- 
induced toxicities, the type II steroid receptor antagonist, mifepris- 
tone (RU-38 486, hereafter called RU486) (Research Biochemicals 
International, Natick, MA) was formulated into 20-mg, 8-d re- 
lease pellets (Innovative  Research of America, Toledo, OH) giving 
100 mg/kg/d. The dose was selected based on previous studies by 
others (26, 27) and our in vivo titrations examining thymic type 
II receptor occupancy  by RU486 in a steroid receptor binding assay 
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type II receptors were occupied by the antagonist.  Pellets containing 
RU486 or placebo control were implanted into mice subcutane- 
ously, in the subscapular region, one day prior to infection. In vivo 
activity of TNF was evaluated utilizing a neutralizing chimeric ham- 
ster/murine anti-TNF monoclonal antibody which has the Fab of 
TN3.19-12 combined with a murine IgG1 Fc region (29).  Mice 
were treated with either 125 or 250/~g of purified antibody in PBS 
on days 0, 2, 4, and 6, relative to infection. The day 0 injection 
was given 3 h before infection with LCMV. Control animals were 
treated with equivalent amounts of similarly purified MOPC21, 
a monoclonal antibody with no known specificity (IgG1) derived 
from X63P3. Under the conditions used, circulating TNF was in- 
hibited by m50-60%  as evaluated in ELISA. 
Preparation and Analysis of Cells and Tissues.  Leukocytes were 
isolated  from macerated whole spleen  after ammonium chloride 
lysis of erythrocytes. Flow cytometric analyses were performed at 
the Roger Williams Cancer Center of Brown University using a 
FACScan (Becton Dickinson, San Jose, CA) with argon laser output 
at  15 row. Analyses of splenic T  cell subsets  were performed as 
described  (9)  using  phycoerythrin-conjugated  rat  monoclonal 
RM-4-5  specific  for mouse  L3T4  to  detect  CD4  and  FITC- 
conjugated rat monoclona153-6.7 specific for mouse Ly-2 to detect 
CD8 (PharMingen, San Diego, CA). Blast size cells were deter- 
mined by analyzing forward scatter plots of gated CD8 + CD4-, 
or  CDf-  CD4 §  cells. Thymus  glands  were  removed  intact, 
trimmed of fat and connective tissue,  and weighed on a Mettler 
PC 220 digital scale (Highstown, NJ). After weighing, glands were 
sectioned, fixed in 10% neutral buffered formalin for at least 15 h, 
Bouins fixative for 6 h, and paraffin embedded. 5-/zm sections were 
stained  with hematoxylin and eosin, and photographed with an 
Olympus OM-1N camera at 30 x  using Kodak Tungsten 64T Film 
and a Hoya neutral density filter. 
Analysis of ViralReflication.  Viral titers were measured in kidneys 
because these organs were readily available in all animals  tested, 
and we have shown that changes  in renal viral titers reflect  the 
changes in other compartments (9). Tissue samples were frozen 
at -80~  thawed, homogenized, and LCMV measured by plaque 
assays on Veto cells as described  (9). 
Preparation of Cellular RNA and Probes  for Hybridization.  Total 
splenic leukocyte RNA was prepared using RNAzol-B (BIOTECX 
LAB., Houston, TX) according to manufacturer's recommenda- 
tions.  TNF-c~  and  glyceraldehyde  3-phosphate  dehydrogenase 
(GAPDH) probes were made from PCR-amplified cloned plasmid 
inserts (30, 31) or cDNA generated by reverse transcription of 1 
/~g of total RNA from C57BL/6 mice using Moloney Murine 
Leukemia Virus reverse transcriptase  (GIBCO BILL, Gaithersburg, 
MD). 5/xl of cDNA template were then added to lx  PCR buffer 
(50 mM KC1, 10 mM Tris-HC1), 0.5 mM dNTPs, 1.5 mM MgC1, 
0.25 U Taq DNA polymerase (Perkin-Elmer Corp., Norwalk, CT) 
and 50 pmol of TNF-c~ or GAPDH-specific primers (Clontech, 
Palo Alto, CA) in a final volume orS0/~1. The 692-base pair TNF-c~ 
and the 983-base pair GAPDH-specific cDNAs were amplified with 
the following cycling conditions: 30 s at 94~  30 s at 60~  I rain 
at 72~  for 30 cycles, followed by a 10-min  extension at 72~ 
Specificity was verified by Southern hybridization using internal 
oligonucleotide probes (Clontech). Specificity of the cDNA for 
TNF-c~ was verified by demonstration of hybridization to cloned 
TNF-c~ but not to cloned TNF-B sequences. An additional nega- 
tive control probe prepared for in situ hybridizations was a 611- 
base pair GC low region amplified  from the baker's yeast SPR1 
gene (32) (gift from Dr. Don Primerano, Marshall University School 
of Medicine,  Huntington, WV). Probes were labeled by random 
priming (Prime-it, Stratagene, La Jolla, CA) with [32p]dCTP for 
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Northern blot analysis or with digoxigenin-dUTP using the Genius 
System Labeling Kit (Boehringer Mannheim Biochemicals,  Indi- 
anapolis, IN) for in situ hybridization. PCR reactions were executed 
in a PTC-100 Programmable Thermal Cycler (MJ Research,  Inc., 
Watertown, MA). 
Northern Blot Analysis.  Northern blot analyses were carried out 
using minor modifications of previously reported techniques (33). 
Briefly, samples were denatured, and separated by electrophoresis 
in a 1.2%  agarose formaldehyde gel.  The RNA was  transferred 
to Hybond-N filters (Amersham Corp., Arlington Heights, IL), 
baked, and prehybridized as recommended by the manufacturer. 
Hybridizations were carried out overnight at 65~  Filters were 
washed with 2x  SSC with 0.1% SDS at room temperature and 
0.1x  SSC and 0.1% SDS at 65~  Films were exposed without 
intensifying screens for linear quantitation.  Where stated, densitom- 
etry was carried out with the Fotodyne Image Analysis System 
(Fotodyne, Hartland,  WI). 
In Situ Hybridization.  Samples were prepared and analyzed using 
modifications  of previously published procedures (34). Briefly, 10- 
#m cryostat splenic sections  were prepared, fixed for 20 min in 
ice-cold 4% paraformaldehyde in PBS, dehydrated in ethanol, and 
stored at -80~  until hybridization. Sections were warmed to room 
temperature before prehybridization as follows: 15 min 0.3% Triton 
)(-100 in 0.1 M Tris base, pH 7.5; 5 min 0.01 M Tris base; 10 min 
in a solution of 1/~g/ml of proteinase K in Tris-EDTA (10 mM 
Tris base, pH 7.5, 1 mM EDTA, pH 8.0) at 37~  rinsed in nuclease- 
free water; rinsed in 0.1 M Triethanolamine,  pH 8.0; 10 min 0.25% 
acetic anhydride in 0.1 M Triethanolamine; 5 rain 0.2x  SSC (So- 
dium chloride, Sodium Citrate buffer); and dehydrated with eth- 
anol. Sections were immediately hybridized with 25/~1 of labeled 
TNF-c~ probe in hybridization buffer overnight at 42~  in a hu- 
midified chamber.  Sections were then washed twice for 10 min in 
2x  SSC, twice for 10 rain in 0.1x  SSC, and once for 15 rain in 
0.1x SSC at 55~  Hybridization was detected by enzyme immuno- 
assay using anti-digoxigenin-alkaline  phosphatase with the substrate, 
nitrobluetetrazolium (NBT) salt, as'described by the manufacturer 
(Nucleic Acid Detection Kit; Boehringer Mannheim Biochemicals). 
Control hybridizations with the PCR amplified yeast probe (see 
above) demonstrated specificity  of the TNF-~ probe. 
In Vitro  Assays.  To evaluate TNF production, conditioned media 
were prepared by suspending  splenic  leukocytes  from I1.-12- or 
control-treated mice (uninfected or day 7 LCMV-infected)  at 1  x 
107 cells/ml in RPMI media (GIBCO) supplemented with 2 mM 
glutamine, sodium bicarbonate,  100 U/ml penicillin, and 100 #g/ml 
streptomycin (GIBCO) and 10% FBS (HyClone Laboratories, Inc. 
Logan, UT). Cell suspensions were incubated in microtiter plates 
(100 #l/well) for 24 h at 37 ~ in a 5% COs incubator. To test for 
sensitivity to TNF, splenic leukocytes from day 6 LCMV-infected 
or uninfected mice were seeded, at 5  x  106 cells/ml, in complete 
RPMI media and 0, 0.1, 1, 10, 100, or 1,000 ng/ml TNF-c~ with 
or without 10 ng/ml II.-12. After incubation at 37~  in 5% COs, 
cells were removed from plates using successive rounds of ice cold 
100% FBS and media washes.  Cells were counted and examined 
for viability by trypan blue exclusion. T cell subsets were analyzed 
by flow cytometry as described above. CTL activity was determined 
by chromium release assay as described (35). Briefly, SlCr (Dupont- 
New England Nuclear, Boston, MA) was used to label uninfected 
or LCMV-infected histocompatible  MC57G target cells (36). Virus- 
specific lysis was determined as the difference between the lysis of 
infected and uninfected cells. Lysis was calculated  as 100  x  (cpm 
test sample supernatant  -  cpm spontaneous release)/(cpm max- 
imum release  -  cpm spontaneous release). Effector to target cell 
ratios of 100:1, 33:1, 11:1, 3:1, and 1:1 were examined and individual 
assays were performed in quadruplicate; replicates  of individual 10 
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Figure  1.  Body weight changes 
in  response  to  1I.-12 treatment 
and/or LCMV infection. Animals 
were weighed before any treatments 
were given and weight change each 
day was calculated based on the ini- 
tial weight measurement. Animals 
were either uninfected (solid lines), 
or LCMV-infected (dashed  lines) and 
Ib12-treated  (solid symbols),  or 
8  treated with vehicle (open symbols). 
Error bars represent SE, n  =  4. 
samples had SD of <10%. Samples were quantified in an Isoflex 
Automatic Gamma Counter (ICN Micromedic Systems, Hunts- 
ville, AL). Lytic units were determined as the number of leuko- 
cytes required to perform  10%  virus specific  lysis on 104 target 
cells. 
Serum Corticosterone Analysis.  Total serum corticosterone was 
measured by radioimmunoassay (R/A) using rabbit antiserum raised 
against corticosterone-21-hemisuccinate  BSA as described (37). Assay 
sensitivity was  10 pg corticosterone. 
Statistics.  The Student's t test was performed where indicated. 
Results 
Physiological  Toxicities Resulting from 11.:I2 Treatment.  Our 
earlier report demonstrated IL-12 induced immunotoxicities 
in LCMV-infected but not uninfected mice, and induction 
of circulating TNF in both groups (9). Gross and histolog- 
ical examinations were carried out to evaluate IL-12-elicited 
physiological changes. Uninfected C57BL/6 mice receiving 
high dose IL-12 (500 ng/d) had slightly ruffled fur and dis- 
played mild lethargy after 7 d of treatment. In contrast, LCMV- 
infected, IL-12-treated mice displayed mild lethargy and ruffled 
fur by day 4 after infection and treatment, which became 
increasingly severe. By day 7 after infection, treated mice were 
hunched and inactive. Internal examination of the IL-12-treated 
animals revealed  blanched internal organs. The alterations were 
more significant in LCMV-infected mice. These changes were 
accompanied by decreases in body weight. After 6 d of treat- 
ment, the IL-12-treated,  uninfected mice displayed weight 
loss of >10% of total body weight (Fig. 1). Weight loss in 
infected IL-12-treated  mice occurred more rapidly and to a 
Table  1.  Effects of High Dose IL-12 and LCMV Infection on  Thymic Mass 
UninfectedS  %  Reduction  d7 LCMV  S  %  Reduction  II 
Experiment*  Uninfected*  + IL-12  uninfected  d7 LCMV*  + IL-12  infected 
mg  mg  mg  mg 
1  49  _+  2  31  •  6  37  47  •  6  14  •  1  70 
2  46  +  5  ND  ND  48  •  3  12  +  2  75 
3  70  •  20  ND  ND  67  •  3  3  •  3  95 
* Experiments  1 and 2,  n  =  4; Experiment  3,  n  =  3.  Results  shown  -+  SE. 
* Mice received daily vehicle injections as control treatment. Injections of infected mice were initiated at 6 h post-infection.  A total of seven injec- 
tions were given. 
Mice received 500 ng/d IL-12. Injections of infected mice were initiated at 6 h after infection.  A  total  of seven injections were  given. 
II Percent reduction of thymic mass by IL-12 and LCMV infection compared to control LCMV infection was significant to p <0.0005 for all values. 
904  IL-12 Toxicity during Viral Infection Figure  2.  Effects  of LCMV infection and II.-12 treatment on thymic morphology. Thymus glands were removed from uninfected, vehicle-treated 
animals (a), day 7 LCMV-infected,  vehicle-treated  animals (b), and day 7 LCMV-infected,  IL-12-treated (500 ng/d) animals (c). Sections  of fixed, paraffin 
embedded glands were stained with H & E.  x30. 
greater  extent  such that  these animals  lost >20%  of body 
weight by day 6  after infection. 
Another change observed in I1:12-treated mice was striking 
thymic atrophy (Table 1). In I1:12-treated,  infected animals 
the thymus had atrophied such that only a small fibrous and 
largely acellular organ with little evidence of  cortical or medul- 
lary structure  remained  (Fig.  2).  In  three different  experi- 
ments the percent decrease in thymic mass in treated, infected 
animals was always statistically significant and greater than 
70% (Table  1). Thymic atrophy evidenced in I1:12-treated, 
uninfected animals was also significant but less extensive than 
in infected animals.  These observations demonstrate that I1:12 
induces physiological toxicities and LCMV infection dramat- 
ically synergizes  to exacerbate these  toxicities. 
11_,12  Induction of TNF Expression In Viva  The aforemen- 
tioned physiological  toxicities  are known to be associated with 
circulating TNF. We have previously shown that in vivo ad- 
ministration of high dose I1:12 induces serum TNF in unin- 
Figure  3.  Northern blot analysis  of  TNF-cx from splenic  mRNA. Total 
cellular RNA was prepared from splenic leukocytes  isolated from mice 
that were uninfected (lane 1  ), day 7 I.CMV-infected  (lane 2), uninfected 
and treated with 500 ng/d IL-12 (lane 3), or infected and treated with 
500 ng/d II.-12 (lane 4). Blots  were prepared and hybridizations were  car- 
ried out as described  in Materials and Methods. Results of hybridization 
with cDNA probes specific  for murine TNF-~ and GAPDH are shown. 
fected mice and LCMV infection synergizes with I1:12  for 
serum TNF induction (9). In vitro experiments were carried 
out to examine TNF production by splenic leukocytes. Leu- 
kocytes from LCMV-infected C57BL/6 mice that had been 
control treated or treated with 500 ng/d IL12 were used to 
condition media for analysis by ELISA. On a per cell basis, 
cells  from  I1:12-treated  LCMV-infected  animals  produced 
128-328 pg/million cells TNF whereas those from control- 
treated LCMV-infected animals produced 34-122 pg/million 
cells. These studies show that I1:12 induces TNF production 
by splenic leukocytes. 
Because antibodies against TNF generally react with both 
TNF-o~ and TNF-B (LT), it is difficult to distinguish the two 
molecules using these reagents.  To specifically  examine in- 
duction of TNF-c~, mRNA was prepared for Northern blot 
hybridization  analysis with a probe specific for TNF-oe (see 
Materials and Methods). Splenic leukocytes from uninfected 
or day 7 LCMV-infected C57BL/6 mice given either vehicle 
or I1:12 were used. Extremely low levels of TNF-o~ were de- 
tected in mRNA from uninfected (Fig.  3, lane 1 ) or day 7 
infected mice (Fig.  3,  lane 2).  Administration  of 500 ng/d 
ILo12 to uninfected animals dramatically induced TNF-~ (Fig. 
3, lane 3). Administration of II:12 to LCMV-infected animals 
induced substantially more TNF-o~ (Fig. 3, lane 4) than did 
either LCMV infection alone or I1:12 administration to unin- 
fected mice.  Densitometric scanning  revealed  that  I1:12 in- 
duced a four- to fivefold increase  in TNF-ol mRNA expres- 
sion in uninfected and a 7-to 10-fold increase in LCMV-infected 
mice. These data demonstrate that the accumulation of TNF-o~ 
mRNA is induced by I1:12 and that there is synergy between 
IL-12 and LCMV infection  for this  induction. 
To evaluate levels of TNF-o~ message per cell and frequency 
of positive cells,  in situ hybridizations were carried out on 
splenic sections as described in Materials and Methods. Unin- 
fected, control-treated  mice showed little  to  no detectable 
TNF-o~ expression (Fig.  4 a). On day 7 after infection with 
905  Orange  et al. Figure 4.  In situ hybridization  for TNF-c~ mRNA. Spleens were harvested from animals that were uninfected, control treated (a), day 7 LCMV- 
infected, control-treated (b), uninfected, 500 ng/d IL-12-treated  (c), and day 7 LCMV-infected, 500 ng/d II.-12  treated (d). Frozen sections were hybridized 
with TNF-~ cDNA probe as described in Materials and Methods. Positive signals were detected in an enzyme immunoassay using alkaline phosphatase 
and nitrobuetetrazolium  substrate.  Tissues were not counterstained,  x30. 
LCMV, there was low TNF-ot expression in an infrequent 
population  of cells (Fig.  4  b).  Compared to LCMV infec- 
tion, 500 ng/d I1.-12 given to uninfected animals induced sub- 
stantially more TNF-ot expression than did I.CMV infection; 
there were more positive ceils with greater intensities in these 
spleens (Fig. 4 c). LCMV-infected animals treated with Ib12 
showed a synergistic induction of TNF  expression (Fig.  4 
d). Individual cells producing TNF in the spleens of Ib12- 
treated animals were significantly more intense and more fre- 
quent.  Thus,  Ib12  treatment not only increased the levels 
per cell, but also the proportions of cells expressing detect- 
able levels of TNF-ot mRNA. Taken together, these studies 
show that IIA2 induces TNF-o~ expression in vivo and that 
LCMV infection synergizes with II.~12 for TNF-ot expression. 
11_,12 Induction of Serum  Corticosterone.  Because TNF can 
stimulate the production  of elevated levels of endogenous 
glucocorticoids (16), the levels of corticosterone were mea- 
sured in IL-12-treated mice. Serum corticosterone was mea- 
sured in samples drawn at early times in the light cycle to 
quantitate changes at the nadir of the diurnal cycle. Adminis- 
tration of Ib12 to uninfected animals induced significant levels 
of serum corticosterone (Fig.  5 a). IL-12 administration and 
LCMV infection induced a threefold increase in corticosterone 
levels compared to uninfected, IL-12-treated animals. Mice 
receiving the first doses of II.-12 on day 1 before infection, 
on the day of infection, 0, or 1 or 2 after infection all had 
high serum corticosterone levels (Fig. 5 b). These high levels 
of corticosterone were specific to IL-12 treatment; equivalent 
amounts of II.-2, on a weight basis,  induced no detectable 
steroid response (Fig. 5 b). These data demonstrate that IL-12 
elicits a significant serum corticosterone response and LCMV 
infection synergizes for this effect. 
Role of Endogenous  TNF in IL-12-Induced Toxicities during 
Infection.  To characterize the role of TNF in IL-12-induced 
toxicities,  anti-TNF monoclonal antibodies were used to neu- 
tralize TNF  in  vivo.  The  neutralization protocols cleared 
•60%  of serum TNF  (see Materials and Methods).  Anti- 
body treatments did not inhibit TNF production as condi- 
tioned  media levels  of TNF  were comparable  to  control 
animals. Serum corticosterone in LCMV-infected, IL-12-treated 
mice was substantially decreased by anti-TNF treatment (Fig. 
6). This demonstrated that IL-12 induced serum corticosterone 
was largely TNF  dependent. 
Anti-TNF treatment had numerous other protective effects 
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Figure  6.  Effects of anti-TNF treatment on I1:12-mediated  induction 
of serum corticosterone, l.CMV-infected  animals were treated with 500 
ng/d I1:12 or vehicle and given a total of either 0.5 mg or I mg chimeric 
hamster/murine anti-TNF TN3.19-12/IgG1 or 1 mg MOPC21 IgG1 in 
four equivalent doses  on days 0,  2, 4, and 6.  Animals were bled under 
low stress conditions on day 7 and serum was evaluated for the presence 
of corticosterone by ILIA. Results presented are the means of 6 animals 
_+ SE. Reduction in serum corticosterone in Ib12-treated animals given 
anti-TNF compared to those given MOPC21 was significant p <0.01 (**). 
in infected, IL12-treated animals.  First,  anti-TNF-treated 
animals displayed less lethargy and fur ruffling at day 7 after 
infection.  These  animals  also  displayed  significantly less 
cachexia and thymic atrophy. Mice given either a total of 0.5 
or 1.0 mg of anti-TNF had about one-half the body (Fig. 
7 a) and thymic (Fig.  7 b) weight losses of control-treated 
infected animals. 
In addition to providing systemic protection from Ib12- 
mediated physiological toxicities, anti-TNF treatment reversed 
much of the immunotoxicity against CD8 + T lymphocytes. 
Administration of anti-TNF to LCMV-infected, IL-12-treated 
mice allowed for a greater expansion of the CD8 + T  cell 
population (Fig.  7 c); anti-TNF-treated animals had greater 
than five million more CD8 + T ceUs per spleen than control- 
treated animals. CTL activity, measured as virus-specific lytic 
units per spleen, was also improved; anti-TNF-treated animals 
had greater than twofold more lytic units per spleen than 
IL,12-treated antibody control-treated animals. The anti-TNF- 
mediated improvements in immune parameters were accom- 
panied by decreased viral replication (Fig.  7 d). Anti-TNF 
treatment allowed for up to a 2 log reduction in renal LCMV 
titers.  Taken together, these data demonstrate that endoge- 
nously produced TNF contributed to all measured toxicities 
induced by IL-12 in LCMV-infected animals, and that TNF 
was pivotal for the Ib12 induction of serum corticosterone. 
Sensitivity of CD8 + T  Cell Responses  to TNF-mediated In- 
hibition.  To characterize sensitivities of in vivo elicited T cell 
populations to TNF-mediated toxicity, experiments were car- 
ried out in culture with splenic leukocyte populations iso- 
lated from uninfected mice and mice on day 6 after infection. 
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Figure 7.  Effects of  anti-TNF 
treatment on parameters of 11,-12-- 
mediated toxicity, l.CMV-infected 
animals were treated with 500 ng/d 
Ib12 or vehicle and given a total of 
either  0.5  mg or  1 mg chimeric 
hamster/murine anti-TNF TN3.19- 
12/IGG1 or 1 mg MOPC21  IgG1 
in 4 equivalent doses on days 0, 2, 
4, and 6. Mice were weighed before 
any treatment was given and then 
weighed on each subsequent day be- 
fore daily injection. Percent weight 
change was calculated using the ini- 
tial reading as standard (a). On day 
7 after infection animals were killed 
and thymus glands were weighed 
(b),  splenic  CD8+  T  cells were 
quantitated by flow cytometry (c), 
viral replication was measured by 
plaque  assay on  Vero cells (d). 
Animals were treated five different 
ways: uninfected with vehicle con- 
trol ([]); l.CMV-infected  with 1 mg 
MOPC21 and vehicle control (I); 
LCMV-in~ct~ with I mg MOPC21 
and 500 ng/d Ib12 ([]);  LCMV- 
infected with 0.5 mg chimeric anti- 
TNF and 500 ng/d IL-]2 (~); and 
I.CMV-infected  with 1 rag chimeric 
anti-TNF and 500 ng/d Ib12 (B) 
Means of four animals are shown 
_+ SE. IL-12-treated animals given 
anti-TNF were statistically different 
from  Ib12-treated animals given 
control antibody p <0.05  (**). 
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Figure 8.  In vitro effects of TNF and/or IL-12 on splenic leukocytes. 
Splenic leukocytes were isolated from uninfected (solid lines) or I.CMV- 
Effects of TNF were examined after 24 h in culture, i.e., day 
7 after infection. TNF concentrations  used were 0, 0.1,  1, 
10, 100 ng/ml. Enhancing effects of II.-12 on TNF activity 
were investigated by adding 10 ng/ml Ib12 along with TNF. 
TNF induced a dose-dependent  decrease in cell viability  of 
populations from infected but not uninfected mice (Fig. 8). 
Addition of IL-12 did not substantially change TNF-mediated 
cytotoxicity.  The decrease in viability was accompanied  by 
a specific inhibition of total  and blast-sized  CD8 + T  cells 
in populations from infected but not uninfected mice (Table 
2). This inhibition was decreased further by addition of Ib 
12 (Table 2). Virus specific lytic units per culture were also 
decreased by TNF and further inhibited by addition of II:12 
(Table 2). These data demonstrated  that the virus-activated 
infected (broken lines) animals on day 6 after infection. Populations were 
incubated for 24 h with either 0, 0.1, 1, 10, or 100 ng TNF-c~/ml, with 
(solid symbols) or without (open symbols) 10 ng/ml IL-12. Cells were har- 
vested from culture plates and viability was measured by trypan blue ex- 
clusion. 
908  Ib12 Toxicity during Viral Infection Table 2.  In  Vitro Effects of TNF or TNF and IL-12 on CD8+  T  Cells frora LCMV-Infected  Animals* 
CD8 + I  Blast CD8 + I  Virus  Specific 
Cells  Cytokines  T  Cells  T  CeUs  Lytic Units 
Uninfected  6.49  0.41  0 
Uninfected  TNF*  6.68  0.48  0 
Uninfected  TNF  +  IL-12  s  8.90  0.64  0 
Uninfected  IL-12)I  6.59  0.40  0 
Day 6  LCMV  18.71  11.50  424 
Day 6  LCMV  TNF*  14.31  5.89  276 
Day 6  LCMV  TNF  +  IL-12s  9.71  2.85  135 
Day 6  LCMV  IL-1211  24.40  9.73  153 
*  Splenic leukocytes  were removed from uninfected,  or LCMV-infected animals on day 6 after  infection,  and placed in culture with or without 
cytokine for 24  h. 
* TNF was  added  to culture at  100 ng/ml. 
S TNF was  added  to culture at  100 ng/ml and  IL-12 was  added  at  10 ng/ml. 
I( IL-12 was  added  to culture at  10 ng/ml. 
I CD8 +  T  cells and blast  CD8 +  T  cells are expressed  as cells recovered from culture  x 10  s. 
** CTL activity is expressed  as LCMV specific lytic units  per culture at  10%  lysis. 
populations were particularly sensitive to TNF-mediated in- 
hibition. 
Role of Endogenous Glucocorticoids in IL-12-induced Toxicities 
during  Infection.  To  evaluate  the  role  of  TNF-induced 
glucocorticoids in the IL-12-induced physiological and im- 
munological toxicities during LCMV infection of C57BL/6 
mice, the type II corticosteroid receptor antagonist, RU486, 
was used.  For these studies,  RU486  was delivered at  100 
mg/kg/d in time-released pellets. Under these conditions two- 
thirds of the available  type II receptors were occupied after 
RU486 treatment (see Materials and Methods). The overall 
appearance of the infected, IL-12-treated mice given RU486 
was not noticeably different than that of infected placebo con- 
trols. Both sets of animals had the previously mentioned signs 
of toxicity, i.e., lethargy, hunching, and ruffled fur. How- 
ever,  Ibl2-treated  animals  given RU486  had  statistically 
significantly larger thymus glands compared to placebo-treated 
animals  (Fig.  9 a).  Moreover,  histological examination of 
thymus from animals receiving RU486 revealed a cellular gland 
with recognizable cortical and medullary regions (data not 
shown). 
Although RU486 reversed thymic atrophy, it did not re- 
store normal immune function or anti-viral status. In con- 
trast  to  the  anti-TNF  treatments  (Fig.  7),  there  was  no 
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Figure  9.  Effects of RU486 on 
parameters  of Ib12-mediated tox- 
icity. An 8-d time release  pellet con- 
taining either RU486  or placebo 
was surgically implanted in mice the 
day before I.CMV infection. RU486 
was administered at ,,o100 mg/kg/d 
from pellets releasing 20 mg over 
8 d at 0.1 mg/h. Mice were either 
vehicle-treated with placebo pellets 
(m), IL-12-treated (500 ng/d) with 
placebo pellets (f~), or IIA2 treated 
with RU486 pellets (Q). Thymic 
mass was measured on an analytical 
balance  (a),  CD8 +  T  cells  were 
quantitated  by flow cytometry (b), 
and viral titers  were measured by 
phque assay on Veto cells (c). Values 
are averages of four mice per group 
and error bars represent SE. RU486- 
treated  animals  were significantly 
different from IL-12-treated control 
animals, p <0.01 where noted ("). Table 3.  Requirement  for IL-2 in Synergy between Viral 
Infection and IL-12 
Mice 
% Enhancement of IL-12-Induced* Changes 
by LCMV Infection 
Weight  Thymic  Serum  Serum 
loss  atrophy  TNF  corticosterone 
IL-2-/-  4.1'  20{{  9~  23* 
IL-2 +  / -  16.4S  43 II  586  s  3894 
* Percent change in IL-12-treated, LCMV-infected mice as compared to 
IL-12-treated, uninfected littermates. Groups of five to eight animals were 
used. 
* Synergy is not significant. 
Synergy is significant p <0.0001. 
{{ Synergy is significant p <0.05. 
Synergy is significant p <0.005. 
significant increase in numbers of CD8 § T  cells (Fig.  9 b) 
or in LCMV titers (Fig.  9 c) resulting from RU486  treat- 
ment  of ID12-treated  infected mice.  There  was  also  no 
significant difference in the CTDmediated virus specific lytic 
units per spleen (data not shown). In Ib12-treated, infected 
animals administered RU486 there was still greater than 200 
pg/ml TNF. Taken together, these results demonstrate that, 
in I1:12-treated mice, serum glucocorticoids were not required 
for the specific immunotoxicities on CD8 + T cell responses 
but did contribute to thymic atrophy. 
11_,2 Requirement for Synergism between 11_,I2 and LCMV In- 
fection.  LCMV infection induces II.-2 (10, 11), and II:2 has 
potent synergy with I1:12 in vitro (38, 39).  Therefore, the 
involvement of endogenous I1.,2 in the synergistic toxicity 
between LCMV and exogenous high dose I1:12 was evalu- 
ated.  For these experiments effects of II:12 administration 
were examined in mice made I1:2 deficient by homozygous 
mutation of the I1:2 gene, or their heterozygous littermates 
(22).  There was a decreased synergy for toxicity between 
LCMV infection and I1:12 administration in IL-2-/- as com- 
pared to I1:2 +/-  littermates (Table 3).  There was 75% less 
decrease in body weight loss and 50% less decrease in thymic 
atrophy between I1:12  treatment and LCMV infection in 
II.-2 -/-  mice as compared to  the  +/-  littermates.  There 
was also 95% less increase in serum TNF and corticosterone 
induction. I1:2-/-  mice were less lethargic and showed less 
ruffling of fur than I1:2 +/- littermates. These data demon- 
strate that I1:2  is required for synergistic induction of en- 
dogenous TNF and corticosterone as well as synergistic phys- 
iologic toxicity between LCMV infection and high dose I1:12 
administration. 
Discussion 
The studies presented here used uninfected and LCMV- 
infected mice to investigate effects of I1:12 treatment. Ib12-in- 
duced TNF factor expression and TNF-c~  mRNA expres- 
sion in vivo. V'wal  infection synergized with administered Ib12 
in this induction. As the synergism was a result of increased 
frequency of TNF-o~ positive cells and dependent upon en- 
dogenous IL-2, it appeared to be a consequence of endoge- 
nous immune responses  to infection. A panel of physiolog- 
ical changes, known to be associated with TNF expression, 
were  induced in  ID12-treated  mice.  These  included:  (a) 
wasting with significant decreases in body weights, (b) elevated 
circulating glucocorticoids, and (c) thymic atrophy. Changes 
in all of these parameters were dramatically elevated in virus- 
infected mice. An additional immunotoxicity was observed 
in the virus-infected mice receiving ID12;  CD8 § CTL  re- 
sponses were profoundly inhibited and viral replication was 
increased.  As antibodies neutralizing TNF reversed the I1: 
12-induced immunotoxicity, wasting, circulating glucocor- 
ticoids, and thymic atrophy, TNF was responsible for all of 
the observed toxicities. Experiments with the type II receptor 
antagonist, RU486, indicated that glucocorticoids were in- 
termediaries in the induction of thymic atrophy. The TNF- 
induced immunotoxicity correlated with an increased senti- 
tivity of virus-dicited lymphocytes to TNF-mediated killing. 
The results clearly demonstrate a mechanism for I1:12-medi- 
ated immunotoxicity. To our knowledge, this is the first report 
of a TNF-mediated inhibition of specific protective immune 
responses.  The results have major implications concerning 
potential detrimental consequences of in vivo TNF induc- 
tion, by any pathway, for expansion of protective CD8 § T 
cell responses  to viral infections. 
The characterization of the profound immunotoxicities 
against CD8 + T cells and anti-viral defenses as TNF-medi- 
ated toxicities is unique. The studies are an extension of our 
earlier work demonstrating II.-12 induction of these immuno- 
toxicities (9), i.e.,  they show that the I1:12-elicited effects 
are dependent upon endogenous TNF (Figs. 7, c and d). The 
earlier report presented experiments examining Ib12 effects 
on in vivo CD8 + T cell numbers in both infected and unin- 
fected mice. Those studies demonstrated that the reduction 
in CD8 + T cell numbers was only apparent in virus-infected 
animals.  Although the differential in vivo sensitivities may 
be in part a consequence of the higher levels of TNF induced 
by ID12 in LCMV-infected mice, the culture studies presented 
here dearly show (a) that in vivo elicited splenic populations 
from infected mice are 3 log more sensitive than those from 
uninfected mice to killing mediated by exogenously added 
TNF (Fig. 8), and (b) that this differential sensitivity is ap- 
parent  in  CD8 +  T  cell populations  (Table  2).  Taken  to- 
gether, the results identify a previously unappreciated toxic 
effect of TNF, i.e., killing of specific T cell populations un- 
dergoing activation and proliferation in response to stimula- 
tion during viral infection. 
The culture studies also indicate that Ib12 is not required 
for but does enhance the immunotoxicity induced by added 
TNF (Fig.  8 and Table 2). ID12 can promote sensitivity of 
ceils to TNF-mediated effects. ID12 has been shown to in- 
duce expression of TNF receptors (2, 39, 40).  Furthermore, 
Ib12 induces IFN-y expression (41) and this factor also in- 
creases sensitivity to and cell priming for TNF-mediated tox- 
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dependently contribute to the increased TNF sensitivity of 
activated T ceils. This factor also induces TNF receptor ex- 
pression (39). Thus, Ib12 administration and/or endogenous 
Ib2 production may promote TNF hyper-responsiveness of 
activated  T  cells. 
The IIA2-induced corticosterone levels reported here were 
as high as 30/zg/dl in sera from day 7 LCMV-infected mice 
(Fig. 5). These levels were in striking contrast to the baseline 
levels in either uninfected or day 7 infected control-treated 
mice, and the modestly induced levels in Ib12-treated unin- 
fected mice. The IIA2-induced corticosterone responses are 
particularly remarkable for two reasons. First, the assay samples 
were collected under low stress conditions at the nadir of 
the mouse diurnal cycle. Thus, the high levels were reached 
without induction through these pathways. Second, the dra- 
matically elevated corticosterone levels could be observed a 
full 24 h after the last IL-12 treatment. This is in contrast 
to studies demonstrating induction of corticosterone in re- 
sponse to other cytokines. Bolus doses  of TNF  (15, 16), 
interleukin-1 (ID1) (16, 44-46), and interleukin-6 (IL-6) (16) 
have all been shown to induce corticosterone. In contrast to 
the IL,12-induced responses, however, corticosterone responses 
to TNF, IL-1, and IL-6 are all short-lived and return to base- 
line levels by 2-6 h after treatment. The relatively long half- 
life of IL-12 and the resulting induction of TNF (Figs. 3 and 
4) (9) are factors which could promote the long-lived cor- 
ticosterone response induced by IL-12. 
Treatments with antibodies neutralizing TNF blocked the 
peak IL12-induced corticosterone responses measured here 
(Fig. 6). Thus, the TNF induced  by IL-12 elicited corticosterone 
induction. These results provide insights about cytokine/glu- 
cocorticoid response cascades induced in other conditions such 
as endotoxic shock induced by gram-negative bacteria  (14, 
47, 48). Studies of experimental endotoxic shock models have 
demonstrated the acute induction of TNF, ID1, and IL-6 (14, 
48), and the induction of a glucocorticoid response to each 
of these cytokines administered alone (15, 16, 44-46). It has 
been suggested that these pathways  are in place to induce 
glucocorticoid-mediated  down-regulation of detrimental im- 
mune responses during endotoxic shock (47). Studies neu- 
tralizing TNF have shown that in vivo elicited TNF plays 
a pivotal role in the induction of ILl and ID6 (14). However, 
the pivotal role of TNF in the induction of the glucocorti- 
coid response has not been previously reported. The studies 
presented here demonstrate that, if TNF is inhibited, cor- 
ticosterone induction is also blocked. 
Both neutralization of TNF (Fig. 7 b) and blocking of the 
type II corticosteroid receptor with the antagonist RU486 
(Fig. 9 a) reversed the thymic atrophy observed in Ib12-treated 
infected mice. Taken together with the demonstrated role for 
TNF in corticosterone induction (Fig. 6), the studies indicate 
that thymic atrophy is secondary to endogenous glucocorticoid 
induction and downstream activation of the intracdlular re- 
ceptor. This is consistent with the known steroid sensitivity 
of thymocytes (17, 49) and previously reported thymic atrophy 
resulting from repeated treatments with other cytokines in- 
ducing devated levels of endogenous corticosterone (46). 
The II~12-induced physiological  toxicities  and elevation 
of endogenous TNF and glucocorticoids seen in this and the 
preceding studies (9) are strikingly similar to those induced 
by lipopolysaccharide  in experimental models of endotoxic 
shock (14, 25, 48, 50).  Interesting new evidence indicates 
that endogenous IL-12 is part of the cytokine cascade elicited 
during endotoxic shock: (a) a factor with the characteristics 
of Ib12 is induced in vivo by endotoxin (51, 52); (b) adminis- 
tration of IL-12 increases lethality in murine models of endo- 
toxic shock induced by the gram-negative bacteria Escherichia 
coli (7); and (c) IL-12 is expressed in the cytokine cascade at 
times preceding TNF expression in certain models of endo- 
toxic shock (53). In contrast to toxicities in response to en- 
dotoxin, however, the toxicities reported here after ID12 ad- 
ministration require additional in vivo conditions provided 
by the viral infection. The magnitude of the TNF response 
induced by 500 ng/d of IL-12 in uninfected mice is clearly 
sub-lethal and precipitates generally mild physiological  changes, 
whereas administration of the same dose to LCMV-infected 
mice gives rise to TNF levels sufficient to induce dramatic 
physiological and pathological changes. The Ib12-treated in- 
fected mice have toxicity in a variety of tissues and undergo 
profound wasting (Fig. 1) and thymic atrophy (Table 1, Fig. 
2). Indeed, LCMV-infected  mice given high enough doses 
of IL-12 (500-1,000  ng/d) for long enough periods of time 
(,'08-9  d) will die (data not shown). Thus, administration 
of IL-12 in the context of the response to this virus drives 
no apparent or marginally apparent toxic effects to extremely 
detrimental effects. These results are particularly significant 
because the doses eliciting toxicity in the context of a viral 
infection are similar to IL-12 doses eliciting protective effects 
in mice infected with intracellular  parasites (4, 6) or bacteria 
(7) and in tumor-bearing mice (8). 
The conditions responsible for the synergism between ex- 
ogenously added ILl2 and LCMV infection are not com- 
pletely understood. We have previously shown that ID2 is 
induced during LCMV infections of normal mice (10, 11), 
and IL-2 has been shown to synergize with IL-12 in vitro to 
promote cytotoxic effector cell activity (3, 54), proliferation 
of activated T cells (55, 56), and IFN-y production (41). Al- 
though the mechanism responsible for known synergism be- 
tween ILl2 and IL-2 may be multifactorial, it results in part 
from reciprocal induction of receptors, i.e., IL-12 induces the 
p55 IL-2R (57) and IL-2 induces the IL-12R (58). The studies 
presented here with Ib2-deficient mice clearly indicate that 
endogenous expression of this factor is required for the syn- 
ergism between infection and IL-12 leading to elevated TNF 
expression, circulating corticosterone,  and the accompanying 
physiological toxicities  (Table 3). These results,  along with 
the demonstrated increase in frequency of cells expressing TNF 
in IL-12-treated infected (Fig. 4 d) as compared to uninfected 
(Fig. 4 c) mice, indicate that the synergism is a direct conse- 
quence of the ongoing immune response. 
The highly significant reversals of toxicities seen with ei- 
ther anti-TNF antibody or RU486 treatments were greater 
than 60 but not 100%.  The level of reversal achieved was 
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treatments, i.e., anti-TNF neutralized ,,050-60%  of the cir- 
culating TNF and RU486 blocked the type II glucocorti- 
coid receptors by "~66% (see Materials and Methods). Thus, 
although the toxicities remaining after treatment may be medi- 
ated by other unidentified factors,  it is more likely that they 
are mediated by residual free TNF or glucocorticoid receptors. 
As we were unable to mediate any additional  blocking by 
delivering higher concentrations of anti-TNF or RU486, the 
conditions used appeared to be as optimal as possible for in 
vivo blocking. 
To sum up the results and their implications,  the studies 
presented here demonstrate profound and detrimental conse- 
quences resulting from II:12 and II.,12-induced TNF during 
viral infections.  They suggest that,  during viral infections, 
any conditions  which  promote  elevated endogenous  IL-12 
and/or TNF expression could be detrimental  to protective 
CD8 §  T  cell responses.  Thus,  infections with  endotoxin- 
positive  bacteria  could  block  anti-viral  CD8 §  T  cell  re- 
sponses and anti-viral  states by inducing elevated Ib12 (53) 
and TNF (12, 13). The results also suggest that, if IL-12 plays 
an enhancing role in CD8 + T  cell responses,  to promote 
these protective responses without inducing inhibitory TNF, 
the levels of endogenously produced II.-12 will have to be 
very low.  The data predict that the physiological  changes 
characterized with endotoxic shock may result from either 
synergism between bacterial and viral infections and/or viral 
infections which induce significant levels oflbl2. These predic- 
tions  may provide insights  into  the Dengue hemorrhagic 
fever/Dengue shock syndrome (DHF/DSS) pathology some- 
times seen during  secondary infections with Dengue virus 
(59). Individuals with DHF/DSS have elevated levels of serum 
TNF (60), IL-2 (61), and IFN-'y (61). Interestingly, Dengue 
virus stimulation  is reported to induce a "helper cytokine" 
sharing certain biochemical characteristics  with Ib12 (62, 63). 
Thus, the results presented here may help to explain a broad 
range of complications reported during other viral infections 
and/or other conditions of viral infection. Finally, the studies 
demonstrate that administration of cytokines, which promote 
protective responses in  one context,  can be detrimental  to 
the host in  the context of particular  endogenous immune 
responses. 
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